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CASE REPORT
CD20 Positive T Cell Lymphoma Involvement of Skin
Ki Yeol Lee, M.D., Su Young Jeon, M.D., Jin Woo Hong, M.D., Young Hun Kim, M.D., 
Ki Hoon Song, M.D., Ki Ho Kim, M.D.
Department of Dermatology, College of Medicine, Dong-A University, Busan, Korea
CD20 positive T cell lymphoma is a rare condition that is 
associated with the coexpressions of CD20 and T cell 
markers, such as, CD3, CD5, or UCHL-1. Positivity for CD20 
in this tumor represents an aberrant immunophenotype, but 
the presence of monoclonal T cell receptor (TCR) gene 
rearrangements and negativity for immunoglobulin heavy 
chain gene rearrangement indicate that this tumor is a T cell 
lymphoma. The majority of cases of CD20 positive T cell 
lymphoma have been reported as immature peripheral T cell 
lymphoma not otherwise specified. However, we believe 
that this disease is likely to be re-listed as a new disease entity 
after its pathogenesis has been elucidated and more cases 
have been evaluated. Here, we present a case of peripheral 
T cell lymphoma coexpressing CD20 and T cell markers with 
a demonstrable TCR gene rearrangement, in a patient who 
had been misdiagnosed as having B cell type lymphoma 4 
years previously. We hypothesize that in this case initially 
circulating normal CD20+ T cell subsets underwent neo-
plastic transformation and CD20 positive T cell lymphoma 
subsequently developed in the lymph node, and then 
recurred in the skin due to systemic disease or metastasized 
from the nodal disease. (Ann Dermatol 23(4) 529∼535, 
2011)
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INTRODUCTION
CD20 positive T cell lymphoma is a rare condition that is 
characterized by the coexpression of CD20 and T cell 
markers, such as, CD3, CD5, or UCHL-1
1. Positivity for 
CD20 in any type of T cell lymphoma represents an 
aberrant immunophenotype, despite the presence of 
various indicators of T cell lymphoma.
CD20 is a transmembrane protein, with a molecular 
weight of 35 to 37 kd, which is expressed early during B 
cell development and lost during terminal B cell diffe-
rentiation into plasma cells
1. Its function is still unclear but 
is suspected to act as a calcium channel in the cell 
membrane. CD20 is classified as a pan-B cell marker, and 
its presence on benign and neoplastic lymphocytes is 
generally considered specific for B-lineage. However, 
recent studies have indicated that peripheral T cell 
lymphomas rarely express CD20
2-10, and because CD20 
expression in T cell lymphoma is rare, obtaining a correct 
diagnosis of this type of CD20 positive lymphoma can be 
difficult. Accordingly, because misdiagnosis has a sub-
stantial impact on therapeutic strategy, careful morpho-
logic evaluation and wide range of immunophenotypic 
tools and molecular genetic studies must be employed to 
achieve an accurate diagnosis. 
Here, we report the case of a 56-year-old man with CD20 
positive peripheral T cell lymphoma who had been 
mistakenly diagnosed as having B cell type lymphoma 4 
years previously.
CASE REPORT
A 56-year-old Korean man visited our department in 
March 2009 with a 1-year history of multiple crusted 
erythematous masses on his face, neck, and left forearm 
(Fig. 1). The patient did not manifest any symptoms, such 
as, itching, pain, tenderness, fever, weight loss, or night 
sweats. In a previous visit to a community hospital in KY Lee, et al
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Fig. 1. Variably sized multiple crusted
erythematous masses on the face, 
neck (A & B), and Left forearm (C).
Fig. 2. Diffuse and pandermal lymphocytic infiltration without epidermal involvement (A: H&E, ×40). The round tumor cells were
small to medium sized with vesicular nuclei and prominent nucleoli and had a relatively monotonous appearance (B: H&E, ×400).
2005, he had been diagnosed as having B cell type 
lymphoma based on the results of a surgical biopsy 
performed on an enlarged lymph node in his neck. 
Subsequently, he underwent 9 cycles of CHOP (cyclo-
phosphamide, adriamycin, vincristine, and prednisone), 
which resulted in clinical remission. However, in 2008, 
small-sized reddish papules appeared on his face and 
grew in size with a firmer consistency than the original 
erythematous masses. New lesions also subsequently 
developed at other skin sites. His clinical differential 
diagnosis was indeterminate but skin metastasis or 
squamous cell carcinoma was suspected. A skin biopsy 
was then performed on a neck mass.
Histopathologically, basophilic tumor cells were found to 
infiltrate diffusely into the deep dermis without epidermal 
involvement. The small to medium sized round tumor 
cells contained vesicular nuclei, prominent nucleoli, and 
adopted a relatively monotonous appearance (Fig. 2). 
Immunohistochemically, the neoplastic cells were positive 
for CD3, CD4, CD5, UCHL-1, CD20, CD79a, and bcl-2 
(Fig. 3). However, CD10, CD30, CD56, CD68, CD138, 
granzyme B, and EBV in situ were not expressed, although 
normal lymphocytes were positivite for CD8 and TIA-1. 
Complete blood cell count, differential cell count, urinalysis, 
and liver function testing (including BUN/Cr) were normal 
as well as peripheral blood smear and a bone marrow 
biopsy were also normal. Computerized tomography 
revealed multiple enlarged tumor masses on the neck with 
lymphadenopathies on the interjugular, submandibular, 
and submental lymph nodes.
We determine the nature of this case, where both T and B 
cell associated antigens were expressed, by performing 
multiplex PCR studies to assess the rearrangement of T 
cell receptor (TCR) gamma and immunoglobulin heavy CD20 Positive T Cell Lymphoma Involvement of Skin
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Fig. 3. Analysis of CD3 (A), CD4 (B), CD5 (C), UCHL-1 (D), CD20 (E), and for aCD79a (F) and bcl-2 (G) (immunoperoxidase stain, 
×400).
chain (IgH). In addition, we histopathologically reviewed 
the biopsy specimen taken in 2005 from a neck lymph 
node, and subjected it to immunophenotypic and geno-
typic analysis.
For the genotypic analysis, 35 cycles of two multiplex 
PCR reactions were performed for TCR gamma gene 
rearrangements on the DNA extracted from 8 μm sections 
that were deparaffinized. The primers used in Mix 1 PCR 
were: V2(5’-CTT-CCT-GCA-GAT-GAC-TCC-TAC-AAC-TCC- 





G-3’), JGT12(5’-AAG-TGT-TGT-TCC-ACT-GCC-AAA-3’), JGT3 
(5’-AGT-TAC-TAT-GAC-CTA-GTC-CC-3’), JGT4(5’-TGT-AAT- 
GAT-AAG-CTT-TGT-TCC-3’). The primers used in the Mix 




CTT-GGG-CAC-TGC-TCT-AAA-3’) and the same three 
joining primers. Jurkat cells were used as positive controls 
and a previous negative sample was used as a negative 
control. Thirty-five cycles of semi-nested PCR for the 
FRIII-J segment were conducted for IgH gene rearran-
gements, using the primers FRIIIA(5’-ACA-CGG-CYS-TGT- 
ATT-ACT-GT-3’), LJH(5’-TGA-GGA-GAC-GGT-GAC-C-3’), 
and VLJH(5’-GTG-ACC-AGG-GTN-CCT-TGG-CCC-CAG- 
3’). The semi-nested first primers were FRIIIA and LJH and 
the second primers were FRIIIA, VLJH. RAJI cells were 
used as positive controls and a previous negative sample 
was used as a negative control. The TCR gamma gene 
rearrangement showed monoclonality at around 200bp in 
our and the previous biopsy specimens, but the IgH gene 
rearrangement showed no monoclonality in either spe-
cimen (Fig. 4).
Histopathologic findings of the neck lymph node biopsy KY Lee, et al
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Fig. 3. Continued.
performed in 2005 revealed the presence of basophilic 
small to medium sized tumor cells infiltrating in a diffuse 
manner that sometimes formed multiple nodules and 
effacement of the normal architecture, which resembled 
that observed in our skin specimen. The immunopheno-
typic evaluation was strongly positive for CD20 and 
weakly reactive to UCHL-1 in the cytoplasm of atypical 
lymphocytes (Fig. 5). In addition, neoplastic cells were 
found to be positive for CD3 and CD4 and negative for 
CD30 (Fig. 6). 
All these findings were compatible with CD20 positive 
peripheral T cell lymphoma. Supposedly, the disease had 
recurred in the skin from systemic disease or metastasized 
from nodal disease. The patient was treated with 
ifosfamide, methotrexate, VP-16 (etoposide), and 
prednisolone chemotherapy regimen and showed partial 
remission and reduction in mass size (Fig. 7).
DISCUSSION 
When CD20 is expressed by T cell lymphoma, derma-
tologists or pathologists find it difficult to reach a correct 
diagnosis. Although CD20 is a pan-B cell marker, it can be 
expressed in some T cell malignancies, as has been 
reported recently
2-10. The entity, described as CD20 po-
sitive T cell lymphoma, has the following characteristic 
features; positive for the CD20 antigen, expression of one 
or more pan-T-cell antigens (CD2, CD3, CD5, or CD7), 
and monoclonal rearrangements of TCR γ or β without 
rearrangement of the IgH gene
2-10.
CD20 positive T cell lymphoma is extremely rare and 
fewer than 40 cases have been reported
11-15. A review of 
the literature revealed that the majority of the reported 
cases involved the lymph node and extranodal invol-
vement was uncommon. CD20 positive T cell lymphoma 
with only skin involvement accounts for 6/35 cases (17%) 
where the skin involvement manifests as cutaneous 
plaques, nodules, or erythematous patches
11.
Several hypotheses have been proposed to explain the 
nature of CD20 positive T cell lymphoma. The first 
hypothesis is that normal circulating CD20 positive T cells 
may undergo neoplastic transformation
6, the second is CD20 Positive T Cell Lymphoma Involvement of Skin
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Fig. 4. T cell receptor gamma gene rearrangement showed monoclononality at around 200 bp in the present and previous biopsy
specimens (A, B), but immunoglobulin heavy chain gene rearrangement showed no monoclonality in either specimen (C, D).
Fig. 5. The immunophenotypic evaluation performed on a neck lymph node excised at the biopsy performed in 2005, was strongly 
positive for CD20 (A, ×400) and weakly reactive with UCHL-1 (B, ×400) in the cytoplasm of atypical lymphocytes.
that CD20 positive cells may react with normal B cells 
distributed among neoplastic T cells, and the third is that 
CD20 may be a marker of normal T cell activation
16,17. 
Based on the consistently of results regarding the presence 
of TCR gene rearrangement and the lack of evidence of 
transformation from B cell lymphoma at the two time 
points in the described case, we believe that initially 
circulating normal CD20＋  T cell subsets underwent 
neoplastic transformation, and that CD20 positive T cell 
lymphoma subsequently developed in a lymph node. 
Furthermore, CD30, another activation marker, was not 
expressed at any time in the described case, despite the KY Lee, et al
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Fig. 6. Immunophenotypic evaluation from a neck lymph node
excised in 2005 was positive for CD3 (A, ×400) and CD4 (B,
×400) and negative for CD30 (C, ×400).
Fig. 7. The patient underwent ifo-
sfamide, methotrexate, VP-16 (eto-
poside), and prednisolone chemo-
therapy and achieved partial remi-
ssion with a decrease in mass size
(A & B: face, neck, C: Left forearm).
fact that the atypical tumor cells were positive for CD20. 
We need to discern this disease from another entity of 
lymphomas. T cell-rich B cell lymphoma can be con-
sidered when less than 10% of large neoplastic B cells are 
admixed with abundant normal reactive T cells in the 
same specimen. However, IgH gene rearrangement 
studies on tissue samples usually show monoclonality
18. 
Anaplastic large cell lymphoma can be discriminated by 
the presence of large cells with horseshoe shaped nuclei 
that are CD30 positive
19. In addition, neoplastic T cells in 
primary cutaneous CD4＋ small/medium-sized pleomor-
phic T-cell lymphoma usually are CD3＋CD4＋ CD8－CD20 Positive T Cell Lymphoma Involvement of Skin
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CD30－ and can be admixed with CD20 positive B cells, 
and thus, it is difficult to differentiate this disease from 
CD20 positive T cell lymphoma. 
Previous studies have shown that rituximab (a humanized 
anti-CD20 monoclonal antibody) can be used to treat 
CD20 positive B cell lymphoma. Rituximab can kill CD20＋ 
cells directly due to its complement-mediated and 
antibody-dependent cell-mediated cytotoxicities, and indi-
rectly by inducing structural changes, apoptosis, and by 
sensitizing cancer cells to chemotherapy20. Accordingly, 
the anti-CD20 monoclonal antibody, which selectively 
targets CD
20, could provide a means of treating CD20 
positive T cell lymphoma.
Although the role of the CD20 antigen in T cell 
lymphomas has yet to be determined, the majority of CD20 
positive T cell lymphoma cases have been reported as 
peripheral T cell lymphoma not otherwise specified
11,21,22. 
We believe that a comprehensive study on the patho-
genesis of CD20 positive T cell lymphoma and follow-up 
of more cases will result in a re-classification of this 
disease as a new disease entity.
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